AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32497234 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Learning (AL) platform
Number of subjects: 23
Study 32497234 — intervention group
Group type: COMPARATOR
Intervention: Traditional Learning Management System (LMS)
Number of subjects: 23
Study 35041442 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 52
Study 35041442 — intervention group
Group type: COMPARATOR
Intervention: Control: Episodic Recent Thinking (ERT)
Number of subjects: 52
Study 35041442 — intervention group
Group type: EXPERIMENTAL
Intervention: EFT
Number of subjects: 52
Study 35041442 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction across groups
Number of subjects: 52
Study 32770640 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg with a loading dose (LD group)
Number of subjects: 555
Study 32770640 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg without a loading dose (NL group)
Number of subjects: 555
Study 32770640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 35333218 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week strength and flexibility program
Number of subjects: 37
Study 35333218 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 33121346 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA‐1777 (V171) 25, 100, 200, or 300 µg
Number of subjects: 179
Study 33121346 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA‐1777 (V171)
Number of subjects: 179
Study 33121346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 32418886 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg twice daily
Number of subjects: 303
Study 32418886 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib 250 mg
Number of subjects: 303
Study 35678747 — intervention group
Group type: EXPERIMENTAL
Intervention: UCLA Alzheimer's and Dementia Care Program
Number of subjects: 1690
Study 616178325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care from clinical pharmacists
Number of subjects: 240
Study 616178325 — intervention group
Group type: COMPARATOR
Intervention: Common care from medical staff (Control Group)
Number of subjects: 240
Study 33293204 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 50
Study 33293204 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to standard care
Number of subjects: 50
Study 32237984 — intervention group
Group type: EXPERIMENTAL
Intervention: Current CST-CR system
Number of subjects: 0
Study 32237984 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical research support
Number of subjects: 0
Study 33481455 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient physical rehabilitation (4-week hospitalization with physical, occupational, and speech therapy)
Number of subjects: 24
Study 34904190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1-2 mg/kg)
Number of subjects: 801
Study 34904190 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.2-0.3 mg/kg)
Number of subjects: 801
Study 34065560 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme in emotional intelligence and social skills (experimental group, n = 55)
Number of subjects: 141
Study 34065560 — intervention group
Group type: COMPARATOR
Intervention: Usual mentoring activities (control group, n = 57)
Number of subjects: 141
Study 32102058 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic Exercise Training (HET)
Number of subjects: 23
Study 32102058 — intervention group
Group type: COMPARATOR
Intervention: Normoxic Exercise Training (NET)
Number of subjects: 23
Study 32102058 — intervention group
Group type: COMPARATOR
Intervention: Both HET and NET
Number of subjects: 23
Study 35224222 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine placental extract (220 mg, orally, once daily for 4 weeks)
Number of subjects: 29
Study 35224222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally, once daily for 4 weeks)
Number of subjects: 29
Study 35224222 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine placental extract
Number of subjects: 29
Study 33190085 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol Turbuhaler®
Number of subjects: 35
Study 33466128 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 artificial pneumothorax (group P)
Number of subjects: 24
Study 33466128 — intervention group
Group type: COMPARATOR
Intervention: Control (group N)
Number of subjects: 24
Study 32286687 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab emtansine (T-DM1) 3.6 mg/kg intravenously every 3 weeks
Number of subjects: 1486
Study 32286687 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab 6 mg/kg intravenously every 3 weeks
Number of subjects: 1486
Study 32286687 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months
Number of subjects: 1486
Study 34156610 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP)
Number of subjects: 142
Study 34156610 — intervention group
Group type: COMPARATOR
Intervention: Conventional biventricular pacing (BiV)
Number of subjects: 142
Study 34523673 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily for 21 days
Number of subjects: 497
Study 34523673 — intervention group
Group type: COMPARATOR
Intervention: Placebo equivalent
Number of subjects: 497
Study 35012011 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised therapeutic exercise group (STE-G)
Number of subjects: 80
Study 35012011 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised exercise group (UE-G)
Number of subjects: 80
Study 35012011 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received patient therapeutic education
Number of subjects: 80
Study 32289518 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance and Impact Training (HiRIT)
Number of subjects: 93
Study 32289518 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric Axial Compression (IAC)
Number of subjects: 93
Study 32289518 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 93
Study 35246117 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative clinics
Number of subjects: 600
Study 35246117 — intervention group
Group type: COMPARATOR
Intervention: Usual care from physicians
Number of subjects: 600
Study 34922023 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week supervised aerobic and anaerobic training program (3 times per week, 60-min sessions)
Number of subjects: 24
Study 34922023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 24
Study 33166726 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SICIp (threshold-tracking at increasing ISIs from 1 to 7 ms)
Number of subjects: 50
Study 33166726 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SICIs (threshold-tracking at increasing ISIs from 1 to 7 ms)
Number of subjects: 50
Study 33166726 — intervention group
Group type: EXPERIMENTAL
Intervention: A-SICI (conventional amplitude measurements)
Number of subjects: 50
Study 33166726 — intervention group
Group type: COMPARATOR
Intervention: T-SICIp and A-SICI
Number of subjects: 50
Study 32150670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure rise time (PRT) during PSV‐VG
Number of subjects: 12
Study 32150670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure rise time (PRT) during SIPPV‐VG
Number of subjects: 12
Study 32150670 — intervention group
Group type: EXPERIMENTAL
Intervention: Short PRT (0.08 seconds) during PSV‐VG
Number of subjects: 12
Study 32150670 — intervention group
Group type: EXPERIMENTAL
Intervention: Different PRTs in either mode
Number of subjects: 12
Study 36275695 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP) with standard treatment
Number of subjects: 0
Study 36275695 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 0
Study 33074943 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequacy of anaesthesia group (AoA group) using Entropy for depth of hypnosis and surgical pleth index for depth of antinociception
Number of subjects: 494
Study 33074943 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring alone (control group)
Number of subjects: 494
Study 32609465 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured postoperative physiotherapy
Number of subjects: 106
Study 32609465 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative approach
Number of subjects: 106
Study 32609465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 34228889 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy (RT) to sites of oligoprogression
Number of subjects: 72
Study 34228889 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy (ST) escalated
Number of subjects: 72
Study 34228889 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy (ST) maintained
Number of subjects: 72
Study 34228889 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy (ST) discontinued
Number of subjects: 72
Study 32838476 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient therapy (higher, rapid class)
Number of subjects: 120
Study 32838476 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient therapy (higher, moderate class)
Number of subjects: 120
Study 32838476 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient therapy (middle, stable class)
Number of subjects: 120
Study 32838476 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient therapy (low, stable class)
Number of subjects: 120
Study 35821572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 58
Study 35821572 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 58
Study 33526043 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS + walking
Number of subjects: 25
Study 33526043 — intervention group
Group type: COMPARATOR
Intervention: tDCS + seated
Number of subjects: 25
Study 33526043 — intervention group
Group type: COMPARATOR
Intervention: sham + walking
Number of subjects: 25
Study 32125080 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program (experimental group)
Number of subjects: 60
Study 32125080 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 33220395 — intervention group
Group type: EXPERIMENTAL
Intervention: E + RT (oral erlotinib 150 mg/d for 2 years or until disease progression or intolerable toxicity and RT 200 cGy/d, 5 d/wk for 6 weeks)
Number of subjects: 20
Study 33220395 — intervention group
Group type: COMPARATOR
Intervention: EP + RT (etoposide 50 mg/m2 intravenously on days 1‐5 and 29‐33; cisplatin 50 mg/m2 intravenously on days 1, 8, 29 and 36; and RT as for E + RT)
Number of subjects: 20
Study 33220395 — intervention group
Group type: EXPERIMENTAL
Intervention: E + RT
Number of subjects: 20
Study 33220395 — intervention group
Group type: COMPARATOR
Intervention: EP + RT
Number of subjects: 20
Study 32550915 — intervention group
Group type: EXPERIMENTAL
Intervention: SC144 (gp130 inhibitor)
Number of subjects: 0
Study 32550915 — intervention group
Group type: EXPERIMENTAL
Intervention: SC144
Number of subjects: 0
Study 32550915 — intervention group
Group type: COMPARATOR
Intervention: Ciclopirox olamine (CPX)
Number of subjects: 0
Study 33211154 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Exercise (EE)
Number of subjects: 24
Study 33211154 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 24
Study 32058426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine low-dose (0.25-0.5 mg/day)
Number of subjects: 233
Study 32058426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine high-dose (1.5-3.0 mg/day)
Number of subjects: 233
Study 32058426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 35210111 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable gel containing hyaluronic acid and berberine hydrochloride
Number of subjects: 66
Study 35210111 — intervention group
Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 66
Study 33685502 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir + Lopinavir/ritonavir
Number of subjects: 240
Study 33685502 — intervention group
Group type: COMPARATOR
Intervention: Favipiravir + Lopinavir/ritonavir placebo
Number of subjects: 240
Study 33685502 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir placebo + Lopinavir/ritonavir
Number of subjects: 240
Study 33685502 — intervention group
Group type: COMPARATOR
Intervention: Favipiravir placebo + Lopinavir/ritonavir placebo
Number of subjects: 240
Study 32133745 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV-IL10
Number of subjects: 12
Study 32133745 — intervention group
Group type: COMPARATOR
Intervention: Phosphate buffered saline (vehicle)
Number of subjects: 12
Study 36343582 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS over the dmPFC
Number of subjects: 70
Study 36343582 — intervention group
Group type: COMPARATOR
Intervention: tDCS over the primary visual cortex
Number of subjects: 70
Study 34552104 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 19
Study 34552104 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 19
Study 34929031 — intervention group
Group type: COMPARATOR
Intervention: Standard cessation advice and NRT (Group A)
Number of subjects: 1563
Study 34929031 — intervention group
Group type: COMPARATOR
Intervention: Quit or substitute advice and NRT (Group B)
Number of subjects: 1563
Study 34929031 — intervention group
Group type: COMPARATOR
Intervention: Quit or substitute advice and NRT and/or e‐cigarettes (Group C)
Number of subjects: 1563
Study 33246499 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (2 units of 200 to 250 mL within 12 hours after randomization, with a second administration of 2 units 24 to 36 hours after the first administration)
Number of subjects: 483
Study 33246499 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 483
Study 33246499 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 483
Study 35012326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg i.v. over 40 minutes) plus psychological therapy
Number of subjects: 96
Study 35012326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg i.v. over 40 minutes) plus alcohol education
Number of subjects: 96
Study 35012326 — intervention group
Group type: COMPARATOR
Intervention: Saline plus psychological therapy
Number of subjects: 96
Study 35012326 — intervention group
Group type: COMPARATOR
Intervention: Saline plus alcohol education
Number of subjects: 96
Study 33637568 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management (performed in 52% of trial patients)
Number of subjects: 133
Study 33637568 — intervention group
Group type: COMPARATOR
Intervention: Registry management (performed in 49% of registry patients)
Number of subjects: 133
Study 33637568 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management (performed in 32% of trial patients)
Number of subjects: 133
Study 33637568 — intervention group
Group type: COMPARATOR
Intervention: Registry management (performed in 36% of registry patients)
Number of subjects: 133
Study 33637568 — intervention group
Group type: COMPARATOR
Intervention: Registry patients
Number of subjects: 133
Study 34330094 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0
Study 34330094 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 0
Study 34330094 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS
Number of subjects: 0
Study 34330094 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS (for neurosurgeons)
Number of subjects: 0
Study 34330094 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS (for radiation oncologists)
Number of subjects: 0
Study 33823966 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-associated cue exposure in abstinent MUD group
Number of subjects: 100
Study 33823966 — intervention group
Group type: COMPARATOR
Intervention: Scrambled trials (no drug-associated cues) in abstinent MUD group
Number of subjects: 100
Study 33823966 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction times in drug cue exposure trials
Number of subjects: 100
Study 36143964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 0
Study 36143964 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ + IFNγ
Number of subjects: 0
Study 36143964 — intervention group
Group type: COMPARATOR
Intervention: Media alone
Number of subjects: 0
Study 36143964 — intervention group
Group type: COMPARATOR
Intervention: IFNγ (atherogenic cytokine)
Number of subjects: 0
Study 33373550 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to medical emergency dataset (MED) during handover process
Number of subjects: 72
Study 33373550 — intervention group
Group type: COMPARATOR
Intervention: No access to medical emergency dataset (MED) during handover process
Number of subjects: 72
Study 34230016 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidy program and standard care
Number of subjects: 3000
Study 34230016 — intervention group
Group type: COMPARATOR
Intervention: Usual antenatal care
Number of subjects: 3000
Study 35913001 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary nurse-led community intervention
Number of subjects: 199
Study 35913001 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 199
Study 33355689 — intervention group
Group type: EXPERIMENTAL
Intervention: Baobab fruit pulp (BFP) drink for 12 weeks
Number of subjects: 58
Study 33355689 — intervention group
Group type: COMPARATOR
Intervention: Isoenergy drink without BFP for 12 weeks
Number of subjects: 58
Study 32253789 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery surgery plus medical therapy
Number of subjects: 0
Study 32253789 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 0
Study 35672893 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC+ETV
Number of subjects: 31
Study 35672893 — intervention group
Group type: COMPARATOR
Intervention: ETV
Number of subjects: 31
Study 34592191 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab
Number of subjects: 0
Study 34592191 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study 35166140 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 34
Study 35166140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 34115380 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab (675 mg)
Number of subjects: 2823
Study 34115380 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab (675 mg for CM, 225 mg for EM)
Number of subjects: 2823
Study 34115380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2823
Study 32788567 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 32788567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35856155 — intervention group
Group type: EXPERIMENTAL
Intervention: High psychological resilience (most resilient BRS group)
Number of subjects: 210
Study 33516726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Number of subjects: 150
Study 33516726 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus aurantium essential oil
Number of subjects: 150
Study 33516726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 150
Study 33483440 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts and Health programme (12 week course)
Number of subjects: 617
Study 33483440 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparable group of children)
Number of subjects: 617
Study 33483440 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts and Health programme
Number of subjects: 617
Study 616173846 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TR) 70 mg/d bid for 3 months, then Ranolazine (RN) 1000 mg/d bid for 3 months
Number of subjects: 276
Study 616173846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (RN) 1000 mg/d bid for 3 months, then Trimetazidine (TR) 70 mg/d bid for 3 months
Number of subjects: 276
Study 35552080 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 120
Study 35552080 — intervention group
Group type: EXPERIMENTAL
Intervention: Shower
Number of subjects: 120
Study 35552080 — intervention group
Group type: COMPARATOR
Intervention: Routine labor care
Number of subjects: 120
Study 34564022 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/kg betaine (group B)
Number of subjects: 300
Study 34564022 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg/kg betaine (group C)
Number of subjects: 300
Study 34564022 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,800 mg/kg betaine (group D)
Number of subjects: 300
Study 34564022 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,400 mg/kg betaine (group E)
Number of subjects: 300
Study 34564022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary betaine (all groups)
Number of subjects: 300
Study 34564022 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg betaine (group A)
Number of subjects: 300
Study 34351386 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC-15L
Number of subjects: 0
Study 34351386 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 32518952 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ibrutinib
Number of subjects: 0
Study 34702168 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized multicomponent exercise program (8-week program including tailored exercises for upper/lower body, flexibility, strength, and balance)
Number of subjects: 300
Study 34702168 — intervention group
Group type: COMPARATOR
Intervention: WHO exercise guidelines (active-control group)
Number of subjects: 300
Study 34702168 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 300
Study 34672473 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 40
Study 34672473 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycerin)
Number of subjects: 40